Mobile

Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ quadrivalent influenza candidate vaccine GSK2321138A (FLU D-QIV), when administered to children 18 to 47 months of...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002587-27

Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ quadrivalent influenza candidate vaccine GSK2321138A (FLU D-QIV), when administered to children 18 to 47 months of age

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To assess the immunological non-inferiority in terms of Geometric Mean Titers (GMTs) of the quadrivalent influ-enza study vaccine (FLU D-QIV) compared to the trivalent influenza vaccine (Fluarix™) in primed and unprimed subjects for the three recommended seasonal strains, 28 days after the last vaccination.

Critère d'inclusion

  • Healthy volunteers (immunisation against influenza in male and female subjects 18 to 47 months of age inclusive)

Liens